Aspreva Pharmaceuticals Corporation (Succesfully Exited)

OncoGeneX Technologies Inc.

Protox Therapeutics Inc. (TSX-V:PRX)

Protiva Biotherapeutics Inc.

Vigil Health Solutions Inc. (TSX-V:VGL)

Xillix Technologies Corp. (Succesfully Exited)

Aspreva Pharmaceuticals Corporation is focused on addressing individuals with less common diseases through the identification, development and commercialization of existing medicines for new indications. BC Advantage Funds invested in Aspreva in 200 and exited the investment in 2006 at a 23.4X return multiple, which won BC Advantage Funds the CVCA Venture Capital Deal of the Year Award.

OncoGeneX Technologies Inc. is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies, designed to inhibit the production of specific proteins associated with treatment resistance, and which are over-produced in response to a variety of cancer treatments.

Protox Therapeutics Inc. (TSX-V:PRX) is at the forefront of developing novel treatments in the emerging field of targeted toxin therapeutics for the treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), in the development of therapeutic products for its clinical programs.

Protiva Biotherapeutics Inc. is a focused on pharmaceutical products to fight cancer, metabolic and infectious disease. Protiva's technology, employing lipid nanoparticles to encapsulate and deliver nucleic acid based drugs, such as siRNA, allows for the development of molecular therapeutics that act selectively at sites of disease.

Vigil Health Solutions Inc. (TSX-V:VGL) offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding aged care market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration.

Xillix Technologies Corp. developed innovative fluorescence endoscopy systems to aid in the detection and localization of cancer. BC Advantage Funds invested in Xillix in 2002 and exited the investment in 2003 generating an approximate 3X return on its investment.